Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Haimen Pharma, officially known as Haimen Jingxin Pharmaceutical Co., Ltd., is a major pharmaceutical manufacturing entity and a core subsidiary of Zhejiang Jingxin Pharmaceutical. Located in the Haimen District of Nantong, China, the company is a leading producer of Active Pharmaceutical Ingredients (APIs) and finished dosage forms, particularly in the cardiovascular and central nervous system (CNS) therapeutic areas. Its key products include widely used medications such as Simvastatin, Sertraline, and various fluoroquinolone antibiotics. Haimen Pharma's facilities are built to international standards, holding certifications from the NMPA, FDA, and EU GMP, which enables it to serve as a significant supplier to global pharmaceutical markets. In addition to its own product line, the company offers comprehensive CDMO services, leveraging its expertise in complex chemical synthesis and large-scale production.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Haimen Pharma.